White-matter changes on MRI as surrogate marker.
This article reviews the use of white-matter changes as identified on MRI as a surrogate marker in clinical trials on vascular dementia. As of yet, insufficient evidence is present to implement rating or volumetric assessment of the burden of white-matter changes as surrogate marker in such trials, in view of the limited sensitivity to change of current methods and the high measurement error.
Scheltens
Philip
P
Department of Neurology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands. p.scheltens@vumc.nl
Barkhof
Frederik
F
Fazekas
Franz
F
D000368:Aged; D015415:Biomarkers; D001921:Brain / Q000098:blood supply* / Q000473:pathology* / Q000503:physiopathology; D002560:Cerebrovascular Circulation / Q000502:physiology; D015140:Dementia, Vascular / Q000473:pathology* / Q000503:physiopathology; D018450:Disease Progression; D006801:Humans; D008279:Magnetic Resonance Imaging; D012680:Sensitivity and Specificity
D015415:Biomarkers